默沙东(MRK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MRK 默沙东

盘后交易 12-11 17:38:56 EST

104.37

+0.62

+0.60%

盘后104.41

+0.04+0.04%

17:33 EST

最高105.47	最低103.57	成交量742.96万
今开104.85	昨收103.75	日振幅1.83%
总市值2,645亿	流通市值2,642亿	总股本25.34亿
成交额7.76亿	换手率0.29%	流通股本25.31亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"MRK","market":"US","secType":"STK","nameCN":"默沙东","latestPrice":104.37,"timestamp":1702328400000,"preClose":103.75,"halted":0,"volume":7429598,"hourTrading":{"tag":"盘后","latestPrice":104.41,"preClose":104.37,"latestTime":"17:33 EST","volume":1234680,"amount":128863514.5596,"timestamp":1702333983902},"delay":0,"floatShares":2531167239,"shares":2534023084,"eps":1.80049,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.62,"latestTime":"12-11 17:38:56 EST","open":104.85,"high":105.47,"low":103.57,"amount":776106728.5890601,"amplitude":0.018313,"askPrice":104.59,"askSize":500,"bidPrice":104.2,"bidSize":3,"shortable":3,"etf":0,"ttmEps":1.80049,"exchange":"NYSE","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1702342800000},"adr":0,"listingDate":-745790400000,"adjPreClose":103.75,"adrRate":0,"dividendRate":0.027594,"preHourTrading":{"tag":"盘前","latestPrice":104.39,"preClose":103.75,"latestTime":"09:29 EST","volume":1441,"amount":149665.624735,"timestamp":1702304996217},"postHourTrading":{"tag":"盘后","latestPrice":104.41,"preClose":104.37,"latestTime":"17:33 EST","volume":1234680,"amount":128863514.5596,"timestamp":1702333983902},"volumeRatio":0.773169},"requestUrl":"/m/hq/s/MRK","defaultTab":"news","newsList":[{"id":"2390125355","title":"更新版 1-莫德纳和默克公司开始进行mRNA癌症疗法的后期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2390125355","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2390125355?lang=zh_cn&edition=full","pubTime":"2023-12-11 20:20","pubTimestamp":1702297216,"startTime":"0","endTime":"0","summary":"(在第2-4段增加了治疗细节和背景资料)    路透12月11日 - 莫德纳   和默克公司（Merck & Co   ）周一表示，他们已经开始了一项晚期试验，将他们的实验性个性化mRNA癌症疗法与大片药物Keytruda联合用于一种肺癌患者。这种名为V940的疗法属于基于m-RNA的个体化新抗原疗法(INT)，它根据肿瘤的特定突变特征为每位患者量身定制，以产生T细胞（人体免疫反应的关键部分）。两家公司表示，该研究的全球招募工作已经开始，首批患者已在澳大利亚注册。莫德纳和默克公司于7月开始了一项晚期研究，在黑色素瘤（最致命的皮肤癌）患者中测试联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2390347243","title":"兴欣新材：公司和陶氏、巴斯夫、东进、京新药业、默克等知名企业建立了紧密的战略合作关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2390347243","media":"全景网","top":-1,"share":"https://www.laohu8.com/m/news/2390347243?lang=zh_cn&edition=full","pubTime":"2023-12-11 17:49","pubTimestamp":1702288140,"startTime":"0","endTime":"0","summary":"兴欣新材首次公开发行股票并在主板上市网上路演于2023年12月11日（星期一）14:00-17:00在全景路演举行。　　路演现场，兴欣新材董事长叶汀表示，公司和陶氏、巴斯夫、东进、京新药业、默克、华峰集团、壳牌、诺力昂等知名企业建立了紧密的战略合作关系。　　了解本次路演提问，请点击：https://rs.p5w.net/html/141199.shtml\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2023-12-11/doc-imzxruey1129706.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2023-12-11/doc-imzxruey1129706.shtml","is_publish_highlight":false},{"id":"2390380848","title":"港股异动 | 和誉-B(02256)涨超4% 附属与默克就Pimicotinib（ABSK021）达成独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2390380848","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2390380848?lang=zh_cn&edition=full","pubTime":"2023-12-11 15:04","pubTimestamp":1702278276,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B涨超4%，截至发稿，涨4.06%，报3.59港元，成交额811.19万港元。消息面上，公司附属和誉医药近期宣布，已与默克公司（就其自主研发的CSF-1R小分子抑制剂Pimicotinib（ABSK021）达成独家许可协议。根据协议条款，默克将获得在中国内地、中国台湾、中国香港和中国澳门针对Pimicotinib就所有适应症进行商业化的许可，和誉医药将保留在授权区域内独家开发Pimicotinib的权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1036164.html","is_publish_highlight":false},{"id":"2390802933","title":"科伦博泰：核心产品SKB264新药申请获药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2390802933","media":"中国网财经","top":-1,"share":"https://www.laohu8.com/m/news/2390802933?lang=zh_cn&edition=full","pubTime":"2023-12-11 09:50","pubTimestamp":1702259400,"startTime":"0","endTime":"0","summary":"中国网财经12月11日讯 科伦博泰今日早间发布公告称，公司核心产品SKB264的新药申请事宜已获药监局受理。科伦博泰宣布，SKB264  用于既往至少接受过2种系统治疗的不可切除的局部晚期或转移性三阴性乳腺癌成人患者的新药申请，已于12月8日获中国国家药品监督管理局药品审评中心受理。SKB264系科伦博泰核心产品。此前，科伦博泰曾遭默沙东终止两款ADC合作权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023121109532383ed46a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023121109532383ed46a3&s=b","is_publish_highlight":false},{"id":"2390058598","title":"市值25亿、BD交易50亿背后，18A企业进入预期修复周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2390058598","media":"氨基观察","top":-1,"share":"https://www.laohu8.com/m/news/2390058598?lang=zh_cn&edition=full","pubTime":"2023-12-10 21:20","pubTimestamp":1702214442,"startTime":"0","endTime":"0","summary":"寒冬还在继续，但对于2024年我们应该更悲观吗？答案，或许是否定的。不考虑宏观因素，聚焦企业层面，我们能看到诸多积极乐观的因素。首先，部分biotech市值已经“触底”，至少不大可能更糟糕了；其次，部分biotech的商业化道路已经非常清晰，不管是自己卖药还是做纯粹的biotech，都开始走上正轨。这一背景下，在销售额表现...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/O_o6FzXDKmyEkdo8Lf2ZKyztvXgheuykTdfiu7RBNyWCAAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/O_o6FzXDKmyEkdo8Lf2ZKyztvXgheuykTdfiu7RBNyWCAAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20231210A06XDL00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20231210A06XDL00","is_publish_highlight":false},{"id":"2389856772","title":"更新版 1-默克-卫材的子宫癌疗法组合未能通过一线治疗试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2389856772","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2389856772?lang=zh_cn&edition=full","pubTime":"2023-12-08 20:15","pubTimestamp":1702037755,"startTime":"0","endTime":"0","summary":"(全文增加细节)    路透12月8日 - 默克  和卫材  周五表示，它们与合作伙伴卫材共同开发的一种联合疗法未能通过晚期试验，该疗法是治疗子宫内膜癌的一线疗法。默克公司的Keytruda和卫材公司的Lenvima联合疗法已在美国和其他国家获得批准，用于治疗某些类型的晚期子宫内膜癌，这些患者之前曾接受过系统治疗。默克公司表示，周五的数据不会影响该联合疗法的批准适应症或其他正在进行的试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2389218330","title":"默沙东的肺癌联合疗法试验未能达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2389218330","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2389218330?lang=zh_cn&edition=full","pubTime":"2023-12-07 22:17","pubTimestamp":1701958632,"startTime":"0","endTime":"0","summary":"默沙东宣布，在一项中期研究中，实验性药物Vibostolimab与Keytruda联合治疗一种肺癌的实验性疗法没有达到主要目标，未能有意义地延缓转移性非小细胞肺癌患者的疾病进展和改善总生存期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120722254883ddc29e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120722254883ddc29e&s=b","is_publish_highlight":false},{"id":"2389047273","title":"更新版 1-默克公司的肺癌药物组合未能达到试验目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2389047273","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2389047273?lang=zh_cn&edition=full","pubTime":"2023-12-07 19:37","pubTimestamp":1701949036,"startTime":"0","endTime":"0","summary":"    路透12月7日 - 默克公司  周四表示，在一项中期研究中，其与Keytruda联合治疗一种肺癌的实验性疗法没有达到主要目标。默克公司的实验性药物Vibostolimab与其大片药物Keytruda联用，未能有意义地延缓转移性非小细胞肺癌患者的疾病进展和改善总生存期。默克 公司的挫折标志着 继罗氏公司的疗法在去年的第二次试验中 ，未能延缓一种肺癌的进展之后，正在探索抗TIGIT 疗法的半打以上公司遭受的第二次重大打击。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2389067729","title":"隔夜美股全复盘(12.7)| 美国11月“小非农”连续第四个月不及预期，三大股指高开低走，纳斯达克中国金龙指数涨0.5%，市场聚焦周五非农数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2389067729","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2389067729?lang=zh_cn&edition=full","pubTime":"2023-12-07 07:24","pubTimestamp":1701905056,"startTime":"0","endTime":"0","summary":"美国11月“小非农”连续第四个月不及预期，三大股指高开低走，纳斯达克中国金龙指数涨0.5%，市场聚焦周五非农数据","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/671330","is_publish_highlight":false},{"id":"2389680330","title":"欧洲股市攀升至四个月高点 德国默克集团股价大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2389680330","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2389680330?lang=zh_cn&edition=full","pubTime":"2023-12-07 02:23","pubTimestamp":1701887028,"startTime":"0","endTime":"0","summary":"欧洲股市周三升至四个月最高水平，因为通货膨胀和劳动力市场的降温迹象增强了投资者的降息预期。德国默克集团下跌，其一种实验性多发性硬化症药物在后期阶段的试验中失败。该国10月份工厂订单意外下降，凸显出这个欧洲最大经济体的制造业仍然停滞不前。欧洲股市在12月份攀升，在过去30年里，平均而言12月是斯托克600指数表现偏正面的一个月份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120702303983d9b7e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120702303983d9b7e9&s=b","is_publish_highlight":false},{"id":"2389776612","title":"更新 1-默克公司因多发性硬化症药物后期试验失败而遭受重大打击","url":"https://stock-news.laohu8.com/highlight/detail?id=2389776612","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2389776612?lang=zh_cn&edition=full","pubTime":"2023-12-06 06:03","pubTimestamp":1701813823,"startTime":"0","endTime":"0","summary":" Ludwig Burger    路透法兰克福12月5日 - 德国默克公司  称，其试验性多发性硬化症药物evobrutinib在备受期待的后期试验中没有达到主要目标，这对该公司的增长雄心造成了重大打击。默克公司周二在一份声明中说，在III期试验中，与赛诺菲公司的   Aubagio相比，evobrutinib未能降低复发性多发性硬化症患者的年复发率。该药物旨在更有选择性地阻断驱动多发性硬化症背后有害的自身免疫反应的细胞，由于该药物类别可能与肝损伤有关，投资者对其收入前景一直心存疑虑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2389727669","title":"默沙东上涨1.22%，报106.34美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2389727669","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2389727669?lang=zh_cn&edition=full","pubTime":"2023-12-06 02:39","pubTimestamp":1701801551,"startTime":"0","endTime":"0","summary":"12月6日，默沙东(MRK)盘中上涨1.22%，截至02:39，报106.34美元/股，成交4.54亿美元。财务数据显示，截至2023年09月30日，默沙东收入总额454.85亿美元，同比增长0.07%；归母净利润15.91亿美元，同比减少86.17%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/12/06023938679643.shtml","is_publish_highlight":false},{"id":"2389293767","title":"港股异动 | 和誉-B(02256)涨超7% 附属和誉医药与默克就Pimicotinib（ABSK021）达成独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2389293767","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2389293767?lang=zh_cn&edition=full","pubTime":"2023-12-05 09:34","pubTimestamp":1701740055,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B涨超7%，截至发稿，涨7.11%，报4.52港元，成交额839.5万港元。消息面上，公司附属和誉医药宣布已与默克公司就其自主研发的CSF-1R小分子抑制剂Pimicotinib达成独家许可协议。根据协议条款，默克将获得在中国内地、中国台湾、中国香港和中国澳门针对Pimicotinib就所有适应症进行商业化的许可，和誉医药将保留在授权区域内独家开发Pimicotinib的权利。此外，和誉医药亦已向默克授予Pimicotinib全球商业化权利的独家选择权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1033401.html","is_publish_highlight":false},{"id":"2388421361","title":"默沙东上涨1.22%，报102.36美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2388421361","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2388421361?lang=zh_cn&edition=full","pubTime":"2023-12-01 00:48","pubTimestamp":1701362932,"startTime":"0","endTime":"0","summary":"12月1日，默沙东(MRK)盘中上涨1.22%，截至00:48，报102.36美元/股，成交2.67亿美元。财务数据显示，截至2023年09月30日，默沙东收入总额454.85亿美元，同比增长0.07%；归母净利润15.91亿美元，同比减少86.17%。大事提醒：11月29日，默沙东获Cantor Fitzgerald重申评级Overweight，目标价上调至135美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/12/01004838632144.shtml","is_publish_highlight":false},{"id":"2387125675","title":"默沙东下跌1.21%，报100.2美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2387125675","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2387125675?lang=zh_cn&edition=full","pubTime":"2023-11-29 03:43","pubTimestamp":1701200584,"startTime":"0","endTime":"0","summary":"11月29日，默沙东(MRK)盘中下跌1.21%，截至03:43，报100.2美元/股，成交3.55亿美元。财务数据显示，截至2023年09月30日，默沙东收入总额454.85亿美元，同比增长0.07%；归母净利润15.91亿美元，同比减少86.17%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/11/29034338607432.shtml","is_publish_highlight":false},{"id":"2385604444","title":"“左手默沙东、右手GSK”之后，1600亿疫苗巨头又要抢滩减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2385604444","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2385604444?lang=zh_cn&edition=full","pubTime":"2023-11-24 11:51","pubTimestamp":1700797865,"startTime":"0","endTime":"0","summary":"A股减肥药概念或再添新军","market":"sg","thumbnail":"https://img3.gelonghui.com/06664-55c6568d-a722-4b1c-8298-abcb950abe7e.jpg","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/06664-55c6568d-a722-4b1c-8298-abcb950abe7e.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/667485","is_publish_highlight":false},{"id":"2385668452","title":"默沙东将以6.1亿美元收购生物技术公司Caraway Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2385668452","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2385668452?lang=zh_cn&edition=full","pubTime":"2023-11-22 23:20","pubTimestamp":1700666410,"startTime":"0","endTime":"0","summary":"默沙东周二宣布，将以6.1亿美元收购生物技术公司Caraway Therapeutics。潜在对价包括一笔未披露的预付款和或有的里程碑付款。Caraway Therapeutics致力于寻求治疗遗传神经退行性疾病和罕见疾病的新疗法。默沙东通过其MRL风险投资基金的投资，自2018年以来一直是Caraway Therapeutics的股东。\n\n现在送您60元福利红包，直接提现不套路~~~快来参与活动吧！\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2023-11-22/doc-imzvpfti8445049.shtml","is_publish_highlight":false},{"id":"2385043509","title":"美国参议院一个委员会要求强生公司和默克制药出席听证会","url":"https://stock-news.laohu8.com/highlight/detail?id=2385043509","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2385043509?lang=zh_cn&edition=full","pubTime":"2023-11-22 07:44","pubTimestamp":1700610280,"startTime":"0","endTime":"0","summary":"美国参议院一个委员会要求 强生 公司和 默克 制药出席听证会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023112207565384332b32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023112207565384332b32&s=b","is_publish_highlight":false},{"id":"2385352156","title":"默沙东斥资6.1亿美元收购生物技术公司Caraway Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2385352156","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2385352156?lang=zh_cn&edition=full","pubTime":"2023-11-21 21:29","pubTimestamp":1700573396,"startTime":"0","endTime":"0","summary":"默沙东周二宣布，将以6.1亿美元收购生物技术公司Caraway Therapeutics。","market":"us","thumbnail":"https://static.tigerbbs.com/fffa3391c464ac9c7b9089af6959b1c0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fffa3391c464ac9c7b9089af6959b1c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1027418.html","is_publish_highlight":true}],"profile":{"websiteUrl":"http://www.merck.com","stockEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0062},{"period":"3month","weight":-0.0486},{"period":"6month","weight":-0.0629},{"period":"1year","weight":-0.0641},{"period":"ytd","weight":-0.0649}],"compareEarnings":[{"period":"1week","weight":0.0024},{"period":"1month","weight":0.0525},{"period":"3month","weight":0.033},{"period":"6month","weight":0.0705},{"period":"1year","weight":0.1614},{"period":"ytd","weight":0.2034}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"默克制药公司于1970年在新泽西州注册成立。公司是一家全球性的医疗保健公司，通过其处方药、疫苗、生物疗法和动物保健品提供创新的健康解决方案。公司的运营主要以产品为基础进行管理，包括四个运营部门，即制药、动物健康、医疗保健服务和联盟部门。","yearOnYearQuotes":[{"month":1,"riseRate":0.55814,"avgChangeRate":0.007613},{"month":2,"riseRate":0.44186,"avgChangeRate":-0.001632},{"month":3,"riseRate":0.627907,"avgChangeRate":-0.003252},{"month":4,"riseRate":0.636364,"avgChangeRate":0.019488},{"month":5,"riseRate":0.659091,"avgChangeRate":0.019791},{"month":6,"riseRate":0.522727,"avgChangeRate":0.013073},{"month":7,"riseRate":0.5,"avgChangeRate":0.005646},{"month":8,"riseRate":0.477273,"avgChangeRate":0.000646},{"month":9,"riseRate":0.545455,"avgChangeRate":-0.005533},{"month":10,"riseRate":0.545455,"avgChangeRate":0.021263},{"month":11,"riseRate":0.727273,"avgChangeRate":0.029373},{"month":12,"riseRate":0.613636,"avgChangeRate":0.013625}],"exchange":"NYSE","name":"默沙东","nameEN":"Merck"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.19.1","shortVersion":"4.19.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"默沙东(MRK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供默沙东(MRK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"默沙东,MRK,默沙东股票,默沙东股票老虎,默沙东股票老虎国际,默沙东行情,默沙东股票行情,默沙东股价,默沙东股市,默沙东股票价格,默沙东股票交易,默沙东股票购买,默沙东股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"默沙东(MRK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供默沙东(MRK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}